Electroconvulsive Therapy on Treatment-resistant Mania in Bipolar Disorder with No Concurrent Antipsychotics: A Case Report

Takako Enokida, Takamasa Noda, Takashi Usami, Naoko Satake, Kazuyuki Nakagome
Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan

Pharmacotherapy is generally the first choice for the treatment of acute mania in bipolar disorder. Electroconvulsive therapy (ECT) is reported to be an effective treatment modality for mania; however, it is usually used as the “last resort.” Herein, we report a case of a patient with treatment-resistant severe mania in bipolar disorder who recovered with ECT without concurrent antipsychotics and mood stabilizers. Our case report showed that ECT monotherapy can be an effective treatment modality for manic state in bipolar disorder, which may lead to a shorter hospital stay and better social outcomes.

KEY WORDS: Mania; Bipolar disorder; Electroconvulsive therapy; Treatment-resistant.

INTRODUCTION

Severe mania presents with various symptoms, such as suicidal or homicidal ideation, aggressiveness, psychosis, and other symptoms, and is an urgent medical condition. Pharmacotherapy is generally the first choice for the treatment of acute mania in bipolar disorder, and lithium, anticonvulsants, and antipsychotics are the mainstay of pharmacotherapy [1-3]. Several meta-analyses on severe mania have reported that the combination of lithium or valproate with antipsychotics is more efficacious than the monotherapy of mood stabilizers [4]. In clinical practice, mood stabilizers and antipsychotics are often used in combination.

Electroconvulsive therapy (ECT) is effective for manic state in bipolar disorder, and ECT should not be considered the “last resort” [5,6]. While randomized controlled trials comparing medication with ECT in mania have not been conducted, a previous report suggested that ECT showed marked improvement in bipolar disorder and could be superior to pharmacotherapy [7]. However, in patients with manic state in bipolar disorder, ECT is advised to only those patients who are refractory and who do not respond to three to six combinations of medications [1,8]. Therefore, the patient in the manic state requires a longer time to undertake ECT. Only a few studies have reported the use of ECT in patients with mania without antipsychotics or mood stabilizers; however, these patients were not completely medication-free.

We, herein, report a patient with mania who underwent ECT without medications. To our knowledge, this is the first case report of the safe administration of ECT for mania with no concurrent medication. Informed consent was provided by the patient for this case report.

CASE

A 39-year-old woman was admitted to our hospital. Nineteen years prior, she was diagnosed with bipolar I disorder in a manic state and was admitted to another hospital. She was prescribed haloperidol; however, soon she developed fever and her creatine kinase (CK) levels were elevated. Malignant syndrome was suspected, and haloperidol was discontinued the day following the fever. She was treated with ECT on the same day. After four sessions of ECT, she had remission of symptoms and was dis-
charged from the hospital. She was prescribed lithium 500 mg per day and sulpiride 150 mg per day. Her prescription was tapered off, and she had been medication-free. She had a final consultation 16 years ago, and was free of significant recurrence of mania or depression in the past 17 years.

She became depressed 2 years ago and became progressively agitated for 1 year. She had trouble of human relationships with colleagues and was finally unemployed (probably fired from her job). She was first admitted to a local hospital. On admission, she presented with agitation and persistent insomnia. On the first day of hospitalization, she made many calls to her coworkers and the fire-department. Aripiprazole 24 mg per day was prescribed, and lithium 200 mg per day was added. Since her manic symptoms did not improve, her prescription was switched from aripiprazole to olanzapine. However, coarse tremor and bilateral knee joint pain appeared. Laboratory data showed elevated CK levels to 384 IU/L; hence, olanzapine and lithium were tapered off. Quetiapine 200 mg per day was initiated; however, coarse tremor, salivation, dysphagia, and CK elevation reappeared. Quetiapine was switched to zotepine; however, salivation and dysphagia reappeared, and hence, zotepine was subsequently tapered. Since it was difficult to control her symptoms by medication, she was transferred to our hospital for further therapy.

She had a past medical history of appendicitis and hyperthyroidism and was on propylthiouracil for 6 months. She had a family history of depression, her mother had depression and her younger sister had postpartum depression. The patient reported that she had never smoked, consumed 700 ml of alcohol per day until before her previous admission, and denied any substance abuse.

On physical examination, she was exacerbated. Her height was 157 cm, body weight was 36 kg, and body mass index was 14.6 kg/m². Results of routine laboratory investigations revealed that CK levels were elevated to 995 IU/L; hence, olanzapine and lithium were tapered off. Results of routine laboratory investigations revealed that CK levels were elevated to 995 IU/L; hence, olanzapine and lithium were tapered off. Quetiapine 200 mg per day was initiated; however, coarse tremor, salivation, dysphagia, and CK elevation reappeared. Quetiapine was switched to zotepine; however, salivation and dysphagia reappeared, and hence, zotepine was subsequently tapered. Since it was difficult to control her symptoms by medication, she was transferred to our hospital for further therapy.

We planned to perform bilateral ECT twice or thrice a week for a total of 12 sessions without mood stabilizers or antipsychotics, and then initiate lithium as a maintenance treatment after the completion of ECT. Flunitrazepam was reduced from 2 to 1 mg, and we excluded zotepine, mosapride citrate hydrate, and triazolam from the preparation for ECT. The patient underwent ECT on the third day of admission to our hospital. In the first session, generalized tonic/clonic seizures were induced, which lasted for approximately 125 seconds, and the patient recovered well. After six sessions, she became less irritated. Furthermore, her tone tempo and quantum of speech decreased. Her YMRS-J score decreased from 44 to 11/60. After seven sessions, she slept well; hence, the dose of flunitrazepam was reduced to 0.5 mg per day. Her YMRS-J score gradually decreased to 2/60 after 12 sessions. She was responsive in every session, and the mean seizure duration was 61.25 seconds. Lithium 200 mg per day was started at the end of the ECT session. Laboratory data showed no abnormalities except for low thyroid-stimulating hormone (TSH) levels. We increased the dose of lithium from 200 to 400 mg per day. She gradually became euphoric and emotionally unstable. Her YMRS-J score was slightly elevated to 11/60. We increased the dose of lithium to 500 mg per day; however, she developed eczema on the face and low TSH levels persisted. She was assumed to have developed destructive thyroiditis caused by lithium. Her quantum of speech started to increase, and her YMRS-J score rapidly increased. We discontinued lithium and started the second term of ECT to treat her manic relapse. Flunitrazepam was terminated, and she was totally drug-free after three sessions. After five sessions, her quantum of speech markedly decreased, and she was in remission. We initiated valproate 400 mg per day, and increased the dose up to 600 mg after one week. Her valproate concentration level was 105 (normal range: 50 – 100), so we decreased the dose to 500 mg per day. She had been in full remission and was subsequently discharged. She started a new job and has maintained remission for one and a half years.
DISCUSSION

Our patient presented with severe symptoms of mania, such as aggressiveness, impaired judgment and decision-making abilities, and psychosis. Despite the severity of her symptoms, we were not able to administer a sufficient dose of antipsychotics because of the side effects, and adequate improvement was not achieved even after the administration of mood stabilizers. Nevertheless, we succeeded in controlling severe mania by ECT without medications. Valproate was used as the maintenance drug after ECT.

Lithium and valproate are usually used as initial treatments for mania; however, their effect has a time interval until response. In addition, antipsychotics have an immediate effect and are often used to sedate and rest manic patients [1,2]. Meta-analyses of 68 randomized trials reported that antipsychotics are more efficacious than mood stabilizers as in the evaluation of a 3-week manic state [9]. Some patients, especially those at risk of self-harm or in a state of high aggression, need immediate response to treatment to protect themselves and others. Severe mania often results in impaired psychosocial functioning, which makes it difficult for patients to maintain relationships in their community. Mania should be treated immediately from both the psychological and social prognosis viewpoints. Therefore, in the cases of poorly tolerated antipsychotics or mood stabilizers, and when mania is too fast to progress or relapse, the duration of hospitalization is prolonged.

ECT provides a rapid clinical response. Nevertheless, the administration of ECT as first-line treatment is usually limited to patients with major depression or with severe psychosis. In bipolar disorder, ECT is not the first choice of treatment. ECT plus pharmacotherapy is indicated secondary for those who fail pharmacotherapy alone, and ECT is found to be effective [6,10]. A review of several case series reported that ECT is safe with lithium [11], but it is still controversial. No consensus regarding performing ECT in patients who are on mood stabilizers is available. In a case series reported in 2005, three manic patients were treated with ECT, one with antipsychotics, another with TSH, and the other with medications of Acquired immunodeficiency syndrome; however, these patients were not completely medication-free [12]. Our case shows that ECT alone can be selected for fast therapy in severe acute manic episodes. Early ECT treatment may lead to shorter hospitalization and better social outcomes for the patients. Acute extrapyramidal syndrome is induced by antipsychotics owning to genetic factors [13]. In our case, the hypersensitivity to antipsychotics may be caused by gene polymorphisms or abnormal metabolizer status for cytochromes P450 family [14]. This is a limited consideration because we did not analyze the genetic polymorphism of the patient.

In conclusion, herein, we report a case of treatment-resistant severe mania in bipolar disorder, in which we had difficulties in prescribing antipsychotics or mood stabilizers because of complications. This case report shows that ECT monotherapy can be an effective treatment modality for mania.

Funding
None.

Conflicts of Interest
No potential conflict of interest relevant to this article was reported.

Author Contributions
Conceptualization: Takako Enokida, Takamasa Noda. Data acquisition: Takako Enokida. Supervision: Kazuyuki Nakagome. Writing—original draft: Takako Enokida. Writing—review & editing: Takako Enokida, Takamasa Noda, Takashi Usami, Naoko Satake, Kazuyuki Nakagome.

ORCID
Takako Enokida https://orcid.org/0000-0002-7343-9300
Takamasa Noda https://orcid.org/0000-0003-0655-9350
Takashi Usami https://orcid.org/0000-0003-2286-8663
Naoko Satake https://orcid.org/0000-0003-3761-6629
Kazuyuki Nakagome https://orcid.org/0000-0003-2919-8180

REFERENCES
1. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 2018;19:2-58.
2. Yatham LN, Kennedy SH, Panikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97-170.
3. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495-553.

4. Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord. 2017;217:266-280.

5. American Psychiatric Association. Task Force on Electroconvulsive Therapy. The practice of ECT: recommendations for treatment, training and privileging. Convuls Ther. 1990;6:85-120.

6. Perugi G, Medda P, Toni C, Mariani MG, Socci C, Mauri M. The role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: effectiveness in 522 patients with bipolar depression, mixed-state, mania and catatonic features. Curr Neuropsychopharmacol. 2017;15:359-371.

7. Abrams R, Taylor MA. Unipolar and bipolar depressive illness. Phenomenology and response to electroconvulsive therapy. Arch Gen Psychiatry. 1974;30:320-321.

8. Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv. 1999;50:201-213.

9. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378:1306-1315.

10. Patel RS, Jain SB, Youssef NA. Electroconvulsive treatment utilization for the inpatient management of severe manic episodes of bipolar disorder. J ECT. 2019;35:195-200.

11. Dolenc Tj, Rasmussen KG. The safety of electroconvulsive therapy and lithium in combination: a case series and review of the literature. J ECT. 2005;21:165-170.

12. Macedo-Soares MB, Moreno RA, Rigonatti SP, Lafer B. Efficacy of electroconvulsive therapy in treatment-resistant bipolar disorder: a case series. J ECT. 2005;21:31-34.

13. MacNeil RR, Müller DJ. Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry. 2016;2:61-78.

14. Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics. 2011;11:1-14.